SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao; hereinafter “SBI Pharma”), a subsidiary company of SBI Holdings, Inc. which conducts research and development pharmaceuticals, etc., utilizing 5-aminolevulinic acid(*) will succeed marketing authorization of “Alabel® Oral 1.5g,” photodynamic diagnostic agent for malignant glioma, in Japan from Nobelpharma Co., Ltd. (Head office: Chuo-ku, Tokyo; Representative Director: Jin Shiomura; hereinafter “Nobelpharma”) as of October 1st, 2024.
SBI Pharma and Nobelpharma have jointly conducted the clinical trial for obtaining the marketing authorization of Alabel in March 2013 of which Nobelpharma became marketing authorization holder based on a license from photonamic GmbH & Co. KG (Head office: Pinneberg, Germany, CEO: Ulrich Kosciessa, Ph.D.; hereinafter “photonamic”）. Now SBI Pharma will succeed the marketing authorization of Alabel based on a license agreement with photonamic GmbH & Co. KG, a subsidiary company of SBI Holdings, Inc. After the transfer, SBI Pharma will promote the proper use and sales as a Marketing Authorization Holder and a Seller.
